Results
Four blinded, placebo-controlled RCT were included in the meta-analysis
and enrolled individuals with mild or moderate SARS-CoV-2 infection. We
found no difference between nitazoxanide and placebo in the frequency of
positive RTP-PCR results (RR = 0.83; 95% CI 0.58 to 1.17) and there was
no decreased risk for disease progression (severe COVID-19, ICU
admission or invasive mechanical ventilation) (RR = 0.40; 95% CI 0.08
to 2.13) and deaths (RR = 0.55; 95% CI 0.18 to 1.68) among patients
receiving nitazoxanide. There were no differences for patients treated
with nitazoxanide and placebo in the levels of inflammatory markers.